SCHEMBL1838406

SCHEMBL1838406

c1cc(-c2ccc3[nH]ccc3c2)c2cc[nH]c2n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NUDT1 P36639 3/20 0.67
▸ PRKCI P41743 7/20 0.66
▸ CCNK O75909 2/20 0.63
▸ CDK12 Q9NYV4 2/20 0.63
▸ IKBKB O14920 3/20 0.58
▸ CHUK O15111 3/20 0.58
▸ AURKB Q96GD4 2/20 0.58
▸ DAPK3 O43293 1/20 0.58
▸ JAK2 O60674 1/20 0.58
▸ PRKD3 O94806 1/20 0.58
▸ MAP4K4 O95819 1/20 0.58
▸ PAK4 O96013 1/20 0.58
▸ CSF1R P07333 1/20 0.58
▸ RET P07949 1/20 0.58
▸ IGF1R P08069 1/20 0.58
▸ FGFR1 P11362 1/20 0.58
▸ PRKACA P17612 1/20 0.58
▸ FLT1 P17948 1/20 0.58
▸ LTK P29376 1/20 0.58
▸ GRK5 P34947 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20839795 0.77 CCNK (0.65) NUDT1PRKCICCNKCDK12IKBKB
SCHEMBL20849864 0.77 CCNK (1.00) NUDT1PRKCICCNKCDK12IKBKB
SCHEMBL14020099 0.77 CCNK (0.58) NUDT1PRKCICCNKCDK12IKBKB
SCHEMBL31420118 0.77 CCNK (0.58) NUDT1PRKCICCNKCDK12IKBKB
SCHEMBL1718138 0.77 NUDT1 (0.67) NUDT1PRKCICCNKCDK12IKBKB
SCHEMBL1717710 0.77 PRKCI (0.61) NUDT1PRKCICCNKCDK12IKBKB
SCHEMBL2240671 0.76 AURKB (0.71) NUDT1PRKCICCNKCDK12IKBKB
SCHEMBL2239087 0.75 IKBKB (0.61) NUDT1PRKCICCNKCDK12IKBKB
SCHEMBL2240782 0.75 AURKB (0.61) NUDT1PRKCICCNKCDK12IKBKB
SCHEMBL17673079 0.75 IKBKB (0.61) NUDT1PRKCICCNKCDK12IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011526931-A — — 2011-10-20 — — JP claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 — — US claimed
CN-102143746-A CDK modulators EXELIXIS INC 2011-08-03 — — CN claimed
EP-2320895-A2 CDK MODULATORS Exelixis, Inc. (US) 2011-05-18 — — EP claimed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 — — WO claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 — — US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 — — US disclosed
CN-102143746-A CDK modulators EXELIXIS INC 2011-08-03 — — CN disclosed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201599-A1 CDK Modulators CDK3, CDK1, CDKL1 NUDT1 2054/4885PRKCI 387/4885CCNK 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback